Story Stocks^®

RadNet (RDNT +8%) is looking pretty rad to investors with shares of the diagnostic imaging company trading sharply higher following its Q2 report. The report featured solid EPS upside and record revenue that topped expectations. Revenue rose 25% yr/yr to $622.7 mln, while RadNet also nudged its FY26 revenue guidance for its Imaging Center segment slightly higher. The results reinforce the improving operating momentum across the core imaging business while highlighting the increasingly important contribution from its higher-growth Digital Health segment.

• Advanced imaging: The record Q2 performance was driven by aggregate advanced imaging (MRI, CT and PET/CT) volume growth of 21.2% and same-center advanced imaging volume growth of +9.6%, both accelerating from 19.7% and +8.2%, respectively, in Q1.
• Digital Health: Digital Health revenue jumped 56.5% yr/yr to a quarterly record of $32.4 mln, while ARR increased to $105.5 mln at June 30 from $53.5 mln a year ago and $96.9 mln at March 31. The business is also becoming less dependent on RadNet's own imaging centers, with external customers now accounting for approximately 63% of Digital Health revenue. RadNet signed approximately $21 mln of new business in Q2, bringing six-month new business Total Contract Value to approximately $37 mln, with most of the awards coming from hospitals and health systems.
• AI opportunity: DeepHealth continues to expand its AI capabilities, highlighted by FDA clearance at the end of July for its breast ultrasound AI solution. RadNet expects to roll out the offering across its breast imaging centers by year-end, with management anticipating both incremental revenue and cost savings from the implementation during 2H26. The clearance provides another tangible catalyst for the company's strategy of combining its imaging footprint with AI-driven healthcare technology.
• Guidance: RadNet modestly raised its FY26 revenue guidance for the Imaging Center segment, providing additional support for the underlying operating outlook. The combination of accelerating advanced imaging volumes, favorable procedural mix and continued Digital Health growth suggests the company is entering the back half of the year with solid momentum.

Briefing.com Analyst Insight

RadNet delivered the type of quarter that can broaden the investor narrative around the company. The EPS and revenue upside were encouraging, but the more important development was the combination of accelerating advanced imaging volumes, improving procedural mix and rapid Digital Health growth. The core imaging business continues to provide a relatively steady earnings foundation, while Digital Health is increasingly giving investors exposure to a much faster-growing AI and enterprise imaging opportunity. The FDA clearance for its breast ultrasound AI solution adds another near-term catalyst, with the potential for both revenue growth and cost savings as the technology rolls out. After trending lower through much of 1H26, RDNT shares have stabilized and begun moving higher. We think investors are increasingly willing to value RadNet less as a traditional diagnostic imaging operator and more as a higher-risk, higher-growth healthcare AI story. That shift in perception could support further upside if Digital Health bookings, ARR growth and AI monetization continue to exceed expectations.